Red Activate

Health Service /Coordinating Clinician Transfusion Laboratory Service
  • Implement national strategies agreed by the Australian Health Protection Principal Committee (AHPPC)/ Council of Australian Governments (COAG), including regarding surgery.
  • Transfer product as directed by governments/NBA /Lifeblood or Suppliers and update BloodNet.
  Red Cell Platelets Plasma (and recombinant products)
Activation
  • Actions in Yellow activation phase have not rectified the situation.
  • BloodNet/National Inventory Template (NIT) indicates continued inability to meet future demand.
  • Product in stock or work in progress (WIP) at a known or potentially high risk of failure.
  • National stock levels are <3  days.
  • National stock levels continue at <0.5 days and may deteriorate further.
  • Current and anticipated supply of platelets to jurisdictions has been compromised.
  • Nil specific.
Action
  • Triage affected products use for life-threatening and other clinically assessed priorities.
  • All requests for affected products must be authorised by a named senior clinician within the health service. These requests will likely need discussion with the NBA and Lifeblood.
  • Track the fate of each unit of affected products.
  • Return unused products to Lifeblood if requested so that they can be reallocated for use at an alternative location.
Desired outcome 
  • Affected products use is triaged for life-threatening and other clinically assessed priorities.
  • Affected products use in elective surgery is restricted and procedures are compliant with jurisdictional emergency arrangements.
  • Ensure national consistency in triage of medical and surgical blood use if situation is sustained.

Refer to RED CELL PRIORITY AND PLATELET PRIORITY LEVELS.

 
Reference

National Blood Authority National Blood Supply Contingency Plan v2.0. July 2019. [Accessed 6 April 2020]. Available from: https://www.blood.gov.au/nbscp

 

<< Previous page: Yellow Activate  |  Next page: Red cell priority levels >>